The effect of cathepsin K deficiency on airway development and TGF-β1 degradation
© Zhang et al; licensee BioMed Central Ltd. 2011
Received: 25 March 2011
Accepted: 31 May 2011
Published: 1 December 2011
Cathepsin K, a cysteine protease predominantly expressed in osteoclasts, is a major drug target for the treatment of osteoporosis. Recent findings, however, indicate that cathepsin K is also involved in non-skeletal metabolism. The development of fibrotic phenotypes in lung and skin is a concern for cathepsin K inhibitors presently evaluated in clinical trials. Cathepsin K is expressed in lung tissue and has been implicated in lung fibrosis. However, little is known about the role of cathepsin K in airway development and its effect on TGF-β1 degradation.
We investigated the effects of cathepsin K-deficiency on alterations in airway integrity, extracellular matrix composition, and TGF-β1 expression and degradation. Lung homogenates of wild-type and cathepsin K-deficient mice were used to evaluate their contents of collagen, glycosaminoglycans, and TGF-β1. The accessibility of TGF-β1 to cathepsin K-mediated degradation was determined in vitro and lung fibroblast proliferations in wild-type and cathepsin K-deficient cells were evaluated.
Lung airway cathepsin K expression in wild-type mice remained constant between 1 and 6 months of age and the airway integrity was maintained. In contrast, after 2 months of age, all Ctsk -/- mice demonstrated increased airway epithelium thickness by 16-28%, a lower structural airway integrity (1-2 score units lower), elevated cytokeratin expression of 12%, increased α-actin and vimentin expression by 50% and 70%, increased area of smooth muscle cells by 15%, elevated hydroxyproline and GAGs content by 20% and 25%, and increased TGF-β1 expression by 25%. TGF-β1 proved an efficient substrate of cathepsin K and TGF-β1 protein content in lung was increased by a potent cathepsin inhibitor. Lung fibroblasts from Ctsk -/- mice after TGF-β1 treatment showed increased proliferation rates, increased levels of TGF-β1 by 30%, and increased ECM secretion.
This study suggests that airway development is partly regulated by cathepsin K and that its expression contributes to the maintenance of the airway structural integrity. The anticipated use of therapeutic cathepsin K inhibitors needs to take potential changes in human lungs into consideration.
Cathepsin K (CatK) is a lysosomal cysteine protease with potent collagenolytic and elastolytic activities. Its predominant expression in osteoclasts and synovial fibroblasts defined the protease as an important mediator of bone resorption and cartilage erosion [1–3]. Selective CatK inhibitors are presently being evaluated in clinical trials for osteoporosis [4, 5]. However, at least one compound failed in phase II clinical trials due to severe skin side effects such as morphea . One major concern of "off-site" effects of CatK inhibitors are fibrotic alterations in lung . CatK downregulation is associated with the development of fibrosis in newborn lungs  and expression levels were significantly lower in lungs of premature infants developing bronchopulmonary dysplasia . On the other hand, increased levels of CatK expression have been reported in lungs after bleomycin and silica treatment and correlated with fibrotic changes in the lung . These data suggest that CatK plays a significant role in lung homeostasis.
Less is known about the effect of CatK activity on airway development and remodeling. Changes in airway structure are common to several pulmonary disorders, such as asthma and lung fibrosis. Changes are characterized by the reconstitution of the epithelium, airway smooth muscle cell hypertrophy and hyperplasia, abnormal deposition, and distribution of extracellular matrix (ECM) [11–13]. In airway remodeling, the equilibrium between production and degradation of ECM is disrupted, leading to a shift in the balance of synthesis and degradation of ECM and the abnormal deposition of matrix components. It has been reported that the secretion of growth factors such as TGF-β1 and altered expression of matrix degrading enzymes such as cathepsins  contribute to structural changes in the ECM. TGF-β1, one of the most potent regulators of connective tissue development, increases lung collagen deposition [15, 16]. Elevated levels of TGF-β1 in lung fibroblast and epithelial cells are associated with the development of airway remodeling during asthma and correlate with the thickening of the basement membrane and the deposition of collagens .
Lung fibroblasts are important in generating a structural framework for the lung and also seem to be active participants in the remodeling process through proliferation and the production of specific mediators. It has been previously shown that epithelial cells, macrophages and fibroblasts express CatK in the lung [18, 19] and that CatK protects against matrix deposition in bleomycin induced lung fibrosis . Interestingly, the level of CatK expression in lungs of silica-treated mice was inversely related to the level of TGF-β1 expression suggesting a link between TGF-β1 and CatK .
The aim of this study is to investigate whether CatK expression directly contributes to the proper airway development via its ECM-degrading potential and/or indirectly by controlling TGF-β1 tissue contents.
Ctsk -/- mice were generated as previously reported . 10 female Ctsk -/- and wild type (WT) mice (C57/BL6 from Jackson Lab) for each age group (1, 2, 3 and 6 months) were included in the study. Mice were fed a chow diet (Mouse Diet 5015, containing 11% fat). All animal experiments were performed in accordance with protocols approved by the local animal care advisory committee.
Histological staining and quantitative image analysis
Mice were anesthetized and lungs were perfused with 10 mL ice-cold phosphate-buffered saline (PBS) through the right ventricle until lung cleared of blood. Then, the lungs were inflated with 10% formalin through the trachea, dissected and stored in 10% formalin for 24 h. Lungs were dehydrated and paraffin-embedded. Sections (5 μm) were processed for hematoxylin/eosin (H&E) and Masson trichrome staining. Microscopic images were acquired with the 20 × objective on a Leica microscope (Leica Microsystems Inc., Wetzlar, Germany) and evaluated with Openlab software (PerkinElmer, Waltham, Massachusetts, USA). The thickness of airway epithelium in H&E stained sections was measured from the base of the airway epithelium to the outer limit of the reticular lamina of the basement membrane at regular intervals of 20 μm with a digital micrometer as described . The integrity of epithelium was assessed by a score system according to the percentage of length of the basement membrane with intact epithelium divided by the total length of the membrane. The intact epithelium has a single layer, orderly lining and no pseudo-stratified ciliated epithelium. The score system corresponds to the following grades: (1) 1, integrity < 15%; (2) 2, 15% ≤integrity < 40%; (3) 3, 40% ≤integrity < 65%; (4) 4, 65% ≤integrity < 85%; (5) 5, 85% ≤integrity. A 30 μm region extending from the airway basement membrane into the parenchyma was analyzed for collagen deposition by trichrome staining. The collagen content was quantified by the percentage of the area of collagen divided by the perimeter of the basement membrane. At least five distal airways from each mouse lung section (perimeter of basement membrane less than 950 μm) were selected for quantification.
Hydroxyproline (HYP) assay and glycosaminoglycan (GAG) assays
Lung tissues were stored at -80°C after harvesting. The frozen lung was pulverized under liquid nitrogen in a mortar. The powdered tissue and the cell pellets were separately incubated with lysis buffer (150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, and 5 mM NaF) containing a protease inhibitor cocktail (Roche, Mannheim, Germany), and were further homogenized by ultrasonication. The supernatants and pellets were separated by spinning at 14,000 g for 20 min at 4°C and protein concentrations were determined using the Bradford assay. The supernatants were kept for immunoblot analysis. The protein from cell culture media was precipitated by addition of 10% trichloroacetic acid in ice cold acetone. Homogenized lung tissue and the precipitations from the media were dried under vacuum at 60°C until a constant weight was obtained. The dried homogenized lung tissue and precipitations were hydrolyzed by autoclaving at 120°C for 20 min twice in the presence of 2 N NaOH. The hydrolysate was used for the HYP assay according to Reddy et al. . After incubation, triplicates of 200 μl of supernatant of the reaction solution were transferred to a 96-well plate and the absorbance at 570 nm was measured within 30 min. The results were calculated as μg of HYP per mg dry tissue weight. Total sulfated glycan content was measured using Blyscan Sulfated Glycosaminoglycan Assay kits (Biocolor, Carrickfergus, County Antrim, UK) according to the manufacturer's instructions. All data were sampled in triplicates.
Sections were incubated with 1% bovine serum albumin for 30 min at room temperature and subsequently incubated at 4°C overnight with mouse anti cathepsin K (1H6: 1:100 dilution, produced by Dr. E. Weber), mouse anti α-smooth muscle actin (1:400, Sigma, Saint Louis, MO) and goat anti-vimentin (1:150, Sigma). Sections were then rinsed and incubated with FITC-conjugated goat anti mouse IgG (1:100, Rockland Immunochemicals Inc., Gilbertsville, PA) and rabbit anti goat IgG (1:100, Rockland) for 30 min at room temperature. For controls, the primary antibodies were replaced by non-immunized goat serum. In the case for CatK immunostaining, Ctsk -/- lung tissue was used. Morphometric quantification of CatK expression in WT mice airways was performed by measuring the area of CatK positive staining inside the airway basement membrane normalized to the perimeter of the basement membrane. Morphometric quantification of airways was performed by calculating the area of actin and vimentin staining encircling the airway divided by the perimeter of the basement membrane. The size of airway SMCs within the sampling area was measured by the total area of airway encircling SMCs (actin staining) divided by the numbers of airway SMCs. For each mouse, five airways were analyzed.
Proteins in lung homogenates and cell lysates were separated by SDS-PAGE and were then transferred onto PVDF membranes. Membranes were incubated with the appropriate primary antibody overnight at 4°C. The concentrations of primary antibodies were as follows: monoclonal mouse anti-α smooth muscle actin (1:5000, Sigma), β-actin (1:10000, Sigma), polyclonal goat anti-vimentin (1:500), rabbit anti-cytokeratin (1:1000, Sigma) and chicken anti-TGF-β1 (1:850, R&D, Minneapolis, MN). Blots were then washed with PBS Tween-20 (PBST) for 10 min three times and incubated for 1 h at room temperature with horseradish peroxidase-conjugated anti-mouse (1:3000, Southern Biotech, Birmingham, AL), anti-goat (1:3000, Southern Biotech), anti-rabbit (1:3000, Southern Biotech) and anti-chicken antibodies (1:1500, R&D), respectively, diluted in PBST. Blots were rinsed 3-times with PBST for 10 min each at room temperature. Then images of the blots were captured and analyzed using the Chemigenius imaging system (Syngene, Cambridge, UK). All values were normalized relative to β-actin loading control. Pixel densities were corrected for background staining in the same membrane.
Cathepsin-dependent TGF-β1 degradation
The pH value of lung homogenates from Ctsk -/- mice were adjusted to pH 5.5 by 3 M acetate buffer. Then 2.5 mM dithiothreitol (final concentration) was added to lung homogenates. The TGF-β1 expression was investigated by two different assays. First, the lung homogenates were incubated with or without human recombinant CatK (1.15 nM, final concentration) at room temperature. Human CatK was expressed in Pichia pastoris as previously described . At 0, 0.5 h, 1 h, 2 h, and 4 h, lung homogenates were transferred into a new tube containing 10 μM E-64 (final concentration) and were incubated another 10 min at room temperature. Second, the lung homogenates were incubated with or without LHVS (10 μM, final concentration) at 650 rpm 28°C for 8 hours. The final products of both assays were analyzed by immunoblot using chicken anti-TGF-β1 (R&D) as primary antibody and corresponding horseradish peroxidase-conjugated rabbit anti-chicken IgY (R&D) as secondary antibody.
Primary mouse lung fibroblasts (MLFs) culture and treatment
After anesthesia, the thorax was opened and lungs were perfused with sterile PBS via the right ventricle until they were pale. Tissues were minced and suspended in Dulbecco's modified Eagle's medium (DMEM, Invitrogen, Carlsbad, CA) containing 0.2% collagenase IV and 0.01% DNase I and incubated with gentle stirring at 37°C for 30 min. After dispersion with collagenase, isolated cells were centrifuged, washed, and cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 1% of L-glutamine, and penicillin, streptomycin, and fungizone. Cultures were re-fed every other day. All cultures were evaluated by immunohistochemistry to assess the expressions of vimentin and cytokeratin. All stained positively with vimentin and but failed to stain for the epithelial cell marker, cytokeratin. Fibroblasts between 2 and 3 passages were used for the assays.
Fibroblasts were incubated in 150 mm plates in 10% FBS/DMEM to reach 70% confluence prior to treatment. TGF-β1 was reapplied every 24 h. At indicated time points, the media was removed from the cells and cells were washed twice with ice-cold PBS. In some experiments, at various time points after incubation of cells, the overlying cell-conditioned medium was removed, stored in sterile tubes in the presence of a protease inhibitor cocktail (Roche, Mannheim, Germany) and frozen at -80°C until used.
Crystal Violet, MTT and wound healing assays
The Crystal Violet assay (CVA) was used to determine fibroblast proliferation. Primary lung fibroblasts were trypsinized and sub-cultured in 24-well plates. Cells were grown in 10% FBS in DMEM to reach 70% confluence, and were then starved with serum free DMEM for 24 h. After starvation, FBS concentration was decreased to 2.5% in the presence or absence of TGF-β1. At selected time points, the cell layer was washed once with PBS. Cells were then fixed and stained by 0.5% crystal violet solution in 25% methanol. After 10 min, the excess dye was removed by washing with tap water. Then, the incorporated dye was solubilized in 1% SDS in PBS, and 200 μl were transferred to a 96-well plate. To determine the cell numbers in each sample, the optical density (OD) was measured directly at a wavelength of 570 nm using a Spectramax Plus reader (Molecular Devices, Sunnyvale, CA).
For the verification of the CVA, the MTT assay [thiazolyl blue, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltertrazolium bromide] (Sigma) was performed to determine fibroblast cell viability and proliferation. On specified time points, the culture media was removed, and fibroblasts were incubated with 0.5 mg/ml MTT solution in an incubator at 37°C for 3 h. After removing the medium, 600 μl of DMSO was added to each well of a 24-well plate to solubilize the blue-colored tetrazolium and the plates were then shaken for 5 min. 200 μl of MTT solution were transferred to a 96-well plate. The absorbance at 570 nm was monitored using a Spectramax Plus reader. Data were expressed as percentage of OD570 nm of TGF-β1 treated sample compared to that of TGF-β1 untreated samples.
Cell scratch assays were used to determine the migration and proliferation rate of cells. Equal numbers of fibroblasts were seeded onto 12-well plate. After 90% confluence being reached, cells were rinsed with PBS and starved in serum free medium for 24 h. Then three uniform wounds were created per well by gently scratching a sterile P-200 pipette tip across the surface of the cultures. Cultures were washed with PBS to remove cellular debris, and cultures were allowed to subsequently incubated for 24 h in DMEM supplemented with 10% FBS. Phase-contrast photomicrographs of the wounds were obtained at 0 and 24 h after injury. The wound area was quantified using the Openlab software. The percentage of the wound healed was determined by the healing area (0 h wound area subtracted by 24 h wound area) divided by the 0 h wound area.
TGF-β1 protein determination by ELISA
Total TGF-β1 content in cell culture supernatants and lung homogenates were determined by ELISA. This assay was performed according to the manufacturer's recommendations (Invitrogen). TGF-β1 concentration was normalized to total protein as determined by micro Bradford Protein Assay. Data are expressed as pg TGF-β1 per mg of protein.
Results are expressed as mean ± SE. All image analyses were performed by two observers blinded to the group status. Score comparisons between groups were performed using the Chi-test. The significance of differences of the mean values was calculated using the one-way ANOVA (t-test). A p value of less than 0.05 was considered significant.
The expression of CatK in mouse small airways
Effect of CatK deficiency on lung development
The airway epithelium of WT mice is organized in a single layer displaying an orderly lining (Figure 1C). In contrast, the airway epithelium of Ctsk -/- mice of two months and older is significantly thicker and disorganized (Figure 1C). From month 2 to 6, the epithelium was about 16-28% thicker in Ctsk -/- mice when compared to WT littermates (Figure 1D). The integrity of the airway epithelium is also altered. In some cases, large zones of epithelium were damaged and disrupted. Using an epithelium integrity score, we observed that from 2 months on, Ctsk -/- mice exhibited integrity scores 1-2 units below that of WT littermates (p < 0.05) (Figure 1E). These alterations were also confirmed by immunoblot analysis evaluating the expression of cytokeratin as a marker of epithelial cells. The expression of cytokeratin was approximately 12% higher in Ctsk -/- mice and correlated with the thickness differences between the two mouse strains (Figure 1F).
Effect of CatK deficiency on extracellular matrix content
Effect of CatK deficiency on TGF-β1contents in lung
Effect of CatK-deficiency on mouse lung fibroblast-like cells (MLFs)
Effect of CatK deficiency on TGF-β1 stimulated proliferation of mouse lung fibroblast (MLF) and wound healing
Airway remodeling is observed in various lung diseases such as asthma and chronic obstructive pulmonary disease . Besides changes in the cellular composition of airways, airway remodeling is characterized by an imbalance between excessive extracellular matrix production and their proteolytic turnover. Proteolytic activities such as matrix metallo- and cysteine proteases have been implicated in lung tissue remodeling [31, 32]. More recently, attention was given to CatK, a papain-like cysteine protease with a potent collagenase and elastase activity. Excess as well as deficiency in CatK expression have been linked to pathological phenotypes. CatK-deficient mice in the bleomycin-induced lung fibrosis model display a stronger fibrotic phenotype than their WT littermates. The phenotype is characterized by a build-up of collagen fibers due to the lack of the collagenase activity . On the other hand, overexpression of CatK leads to increased collagen degradation and a partial protection from bleomycin and silica-induced fibrosis [10, 20]. It was shown that TGF-β1 down-regulates the expression of CatK in silica-induced lung fibrosis and that the level of CatK expression is inversely related to the expression of TGF-β1 and the susceptibility to lung fibrosis . In our present study, we specifically focused on the effect of CatK deficiency on airway development and suggest that the role of CatK is not limited to its matrix protein degrading activity but also affects the proteolytic control of the profibrotic factor, TGF-β1. Our results demonstrated that CatK deficiency in mice correlates with increased thickness and reduced structural integrity of the epithelium, an increase in the sizes and numbers of SMCs as well as with elevated contents of collagen and GAGs. These changes appear to be in part induced by increased levels of TGF-β1 in Ctsk -/- lungs. CatK can reduce the tissue content of TGF-β1 by its ability to specifically degrade the growth factor. Furthermore, lung fibroblasts from Ctsk -/- mice showed increased migration and proliferation rates. TGF-β1 expression and ECM production were more evident in Ctsk -/- lung fibroblasts than in WT lung fibroblasts. Interestingly, the specific CatK inhibitor, balicatib, was reported to increase intact parathyroid hormone levels in clinical human trials for osteoporosis by 50% (discussed in ) corroborating the potential of CatK to degrade regulatory factors.
The increased thickness of the epithelium and its loss of integrity in Ctsk -/- mice can be understood in several ways. First, the proliferation of airway epithelium dominates over apoptosis and necrosis . The proliferative response in the airway epithelium may result in epithelial hyperplasia and thickening resulting in a disorganized epithelium. Cathepsin expression has been implicated in apoptosis  and we have evidence that overexpression of CatK increases apoptosis rates in lung fibroblasts (Zhang and Bromme, unpublished data). Second, the proliferative underlying cells such as SMCs and fibroblasts may migrate into the airway epithelium. Under the stimuli from mediators such as TGF-β1 these migrating cells may be transformed into myofibroblasts  which will produce more matrix proteins . Third, the predominance in mesenchymal cells (including fibroblasts, myofibroblasts, and SMCs) and the lack of CatK expression may also increase the deposition of ECM under the basement membrane . The abnormal ECM surrounding the airways may secret more mediators, which promotes epithelial thickening and remodeling . The ECM itself may also affect the growth of airway epithelial cells and influence epithelial thickness . Taken together, all these changes favor alterations in the airway structure.
Hypertrophy and hyperplasia of SMCs within the airway contribute to changes in the airway structure [41, 42]. This study is the first to report that SMC hypertrophy is linked to CatK deficiency. The propensity for SMCs to grow when CatK is deficient may be linked to the sensitivity of the SMC to growth factors and altered pattern of matrix composition . We observed epithelium thickening and loss of structural integrity as well as abnormal subepithelial collagen deposition within the airway wall. We also revealed that the level of TGF-β1 protein content in whole lung homogenates has been elevated in Ctsk -/- mice. This was consistent with van den Brûle's results that the level of CatK expression in silica-induced lung fibrosis was inversely related to the level of TGF-β1 expression . The elevated level of TGF-β1 may induce SMC hypertrophy and hyperplasia . On the other hand, the increasing ECM deposition in Ctsk -/- mice may promote the survival, proliferation, migration and cytokine synthesis of airway SMCs . TGF-β1 may induce fibroblast differentiation into myofibroblasts  which results in increased ECM production. Then the ECM may subsequently act as a proliferation and migration factor for fibroblasts, thus leading to further airway remodeling. In this study, we have demonstrated that lung homogenates from Ctsk -/- mice released more TGF-β1, which in turn led to an increase in ECM components such as HYP and GAGs. The TGF-β1 content in lung homogenates could be also increased by the addition of a potent CatK inhibitor such as LHVS. The increased TGF-β1 level was also accompanied by an increased thickness of the surrounding airway smooth muscle layer.
There is evidence that fibroblasts are the main cellular source of the extracellular collagen matrix deposition [47, 48]. These cells are themselves excellent sources of CatK [18, 33] and TGF-β1 . Under physiological condition, fibroblasts responding to mediators (including TGF-β1 produced by parenchymal cells) can release TGF-β1. Our data indicate that CatK can decrease TGF-β1 tissue levels and therefore control its overall expression and subsequent secretion. It is tempting to speculate that CatK acts as a regulator of TGF-β1 contents produced by fibroblasts. In Ctsk -/- mice, TGF-β1 levels were elevated. Increased concentrations of TGF-β1 could then drive airway remodeling both through cell proliferation and enhanced matrix production. Although our data clearly suggest that CatK is involved in TGF-β1 regulation, many questions such as the exact site of TGF-β1 degradation (extra- or/and intracellular) as well as the potential proteolytic effect of CatK on the TGF-receptor remain open.
In this study, we demonstrated that CatK deficiency mediates airway development and reason that TGF-β1 signaling is partly controlled by the degradation of the growth factor by CatK. The hypothesis that CatK can increase TGF-β1 tissue levels is supported by several lines of evidence. First, we have shown that TGF-β1 levels are elevated in lungs of Ctsk -/- mice and CatK-deficient MLFs when compared to the growth factor levels in WT mice and MLFs. Second, we demonstrated that CatK can specifically decrease TGF-β1 levels in Ctsk -/- lung homogenates and that TGF-β1 expression is increased in the presence of the cathepsin inhibitor, LHVS. Third, it has been shown by others that the level of CatK transcription is strongly upregulated following silica treatment, and that CatK expression was negatively correlated with TGF-β1 expression . Altogether, these results suggested that interactions between CatK and TGF-β1 contribute to airway development.
In conclusion, we demonstrated that CatK plays a significant role in mouse airways. Our findings caution that anti-CatK targeted therapies such as presently developed for the treatment of osteoporosis may have the potential to induce lung remodeling processes. Further elucidation of the role of CatK in healthy and diseased airways will provide us with invaluable insight into the processes that lead to the development of lung diseases.
The authors gratefully thank Dr. Lari Häkkinen and Andre K.S. Wong for their constructive suggestions. This work was supported by the ICSDP Canada grant and a Canada Research Chair Award (D. B.).
- Yasuda Y, Kaleta J, Bromme D: The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev. 2005, 57 (7): 973-993. 10.1016/j.addr.2004.12.013.View ArticlePubMedGoogle Scholar
- Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee-Rykaczewski E, Coleman L, Rieman D, Barthlow R, et al: Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem. 1996, 271: 12511-12516. 10.1074/jbc.271.21.12511.View ArticlePubMedGoogle Scholar
- Hou WS, Li Z, Gordon RE, Chan K, Klein MJ, Levy R, Keysser M, Keyszer G, Bromme D: Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation. Am J Pathol. 2001, 159 (6): 2167-2177. 10.1016/S0002-9440(10)63068-4.View ArticlePubMedPubMed CentralGoogle Scholar
- Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC, Ince BA: Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010, 25 (5): 937-947.PubMedGoogle Scholar
- Eastell R, Nagase S, Ohyama M, Small M, Sawyer J, Boonen S, Spector T, Kuwayama T, Deacon S: Safety and efficacy of the Cathepsin K inhibitor, ONO-5334, in postmenopausal osteoporosis - the OCEAN study. J Bone Miner Res. 2011Google Scholar
- Peroni A, Zini A, Braga V, Colato C, Adami S, Girolomoni G: Drug-induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol. 2008, 59 (1): 125-129. 10.1016/j.jaad.2008.03.009.View ArticlePubMedGoogle Scholar
- Bromme D, Lecaille F: Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs. 2009, 18 (5): 585-600. 10.1517/13543780902832661.View ArticlePubMedPubMed CentralGoogle Scholar
- Buhling F, Waldburg N, Kruger S, Rocken C, Wiesner O, Weber E, Welte T: Expression of cathepsins B, H, K, L, and S during human fetal lung development. Dev Dyn. 2002, 225 (1): 14-21. 10.1002/dvdy.10134.View ArticlePubMedGoogle Scholar
- Knaapi J, Lukkarinen H, Kiviranta R, Steiner A, Lassus P, Andersson S, Kaapa P: Cathepsin K expression is diminished in infants with bronchopulmonary dysplasia. Acta Paediatr. 2006, 95 (10): 1298-1300. 10.1080/08035250600586492.View ArticlePubMedGoogle Scholar
- van den Brule S, Misson P, Buhling F, Lison D, Huaux F: Overexpression of cathepsin K during silica-induced lung fibrosis and control by TGF-beta. Respir Res. 2005, 6: 84-10.1186/1465-9921-6-84.View ArticlePubMedPubMed CentralGoogle Scholar
- Pardo A, Selman M: Molecular mechanisms of pulmonary fibrosis. Front Biosci. 2002, 7: d1743-1761. 10.2741/pardo.View ArticlePubMedGoogle Scholar
- Vignola AM, Mirabella F, Costanzo G, Di Giorgi R, Gjomarkaj M, Bellia V, Bonsignore G: Airway remodeling in asthma. Chest. 2003, 123 (3 Suppl): 417S-422S.View ArticlePubMedGoogle Scholar
- Hirakawa H, Pierce RA, Bingol-Karakoc G, Karaaslan C, Weng M, Shi GP, Saad A, Weber E, Mariani TJ, Starcher B, et al: Cathepsin S deficiency confers protection from neonatal hyperoxia-induced lung injury. Am J Respir Crit Care Med. 2007, 176 (8): 778-785. 10.1164/rccm.200704-519OC.View ArticlePubMedPubMed CentralGoogle Scholar
- Koslowski R, Knoch K, Kuhlisch E, Seidel D, Kasper M: Cathepsins in bleomycin-induced lung injury in rat. Eur Respir J. 2003, 22 (3): 427-435. 10.1183/09031936.03.00112903.View ArticlePubMedGoogle Scholar
- Hashimoto S, Gon Y, Takeshita I, Matsumoto K, Maruoka S, Horie T: Transforming growth Factor-beta1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinase-dependent pathway. Am J Respir Crit Care Med. 2001, 163 (1): 152-157.View ArticlePubMedGoogle Scholar
- Kenyon NJ, Ward RW, Last JA: Airway fibrosis in a mouse model of airway inflammation. Toxicol Appl Pharmacol. 2003, 186 (2): 90-100. 10.1016/S0041-008X(02)00025-X.View ArticlePubMedGoogle Scholar
- Sagara H, Okada T, Okumura K, Ogawa H, Ra C, Fukuda T, Nakao A: Activation of TGF-beta/Smad2 signaling is associated with airway remodeling in asthma. J Allergy Clin Immunol. 2002, 110 (2): 249-254. 10.1067/mai.2002.126078.View ArticlePubMedGoogle Scholar
- Buhling F, Waldburg N, Gerber A, Hackel C, Kruger S, Reinhold D, Bromme D, Weber E, Ansorge S, Welte T: Cathepsin K expression in human lung. Adv Exp Med Biol. 2000, 477: 281-286.View ArticlePubMedGoogle Scholar
- Bühling F, Gerber A, Häckel C, Krüger S, Köhnlein T, Brömme D, Reinhold D, Ansorge F, Welte T: Expression of cathepsin K in lung epithelial cells. Am J Respir Crit Care Med. 1999, 20: 612-619.Google Scholar
- Srivastava M, Steinwede K, Kiviranta R, Morko J, Hoymann HG, Langer F, Buhling F, Welte T, Maus UA: Overexpression of cathepsin K in mice decreases collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis. Respir Res. 2008, 9: 54-10.1186/1465-9921-9-54.View ArticlePubMedPubMed CentralGoogle Scholar
- Saftig P, Wehmeyer O, Hunziker E, Jones S, Boyde A, Rommerskirch W, von Figura K: Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin K-deficient mice. Proc Natl Acad Sci USA. 1998, 95: 13453-13458. 10.1073/pnas.95.23.13453.View ArticlePubMedPubMed CentralGoogle Scholar
- Sullivan P, Stephens D, Ansari T, Costello J, Jeffery P: Variation in the measurements of basement membrane thickness and inflammatory cell number in bronchial biopsies. Eur Respir J. 1998, 12 (4): 811-815. 10.1183/09031936.98.12040811.View ArticlePubMedGoogle Scholar
- Reddy GK, Enwemeka CS: A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem. 1996, 29 (3): 225-229. 10.1016/0009-9120(96)00003-6.View ArticlePubMedGoogle Scholar
- Linnevers CJ, McGrath ME, Armstrong R, Mistry FR, Barnes M, Klaus JL, Palmer JT, Katz BA, Brömme D: Expression of human cathepsin K in Pichia pastoris and preliminary crystallographic studies of an inhibitor complex. Protein Science. 1997, 6: 919-921.View ArticlePubMedPubMed CentralGoogle Scholar
- Halayko AJ, Salari H, Ma X, Stephens NL: Markers of airway smooth muscle cell phenotype. Am J Physiol. 1996, 270 (6 Pt 1): L1040-1051.PubMedGoogle Scholar
- Peng Q, Lai D, Nguyen TT, Chan V, Matsuda T, Hirst SJ: Multiple beta 1 integrins mediate enhancement of human airway smooth muscle cytokine secretion by fibronectin and type I collagen. J Immunol. 2005, 174 (4): 2258-2264.View ArticlePubMedGoogle Scholar
- Brömme D, Klaus JL, Okamoto K, Rasnick D, Palmer JT: Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. Biochem J. 1996, 315: 85-89.View ArticlePubMedPubMed CentralGoogle Scholar
- Kotaru C, Schoonover KJ, Trudeau JB, Huynh ML, Zhou X, Hu H, Wenzel SE: Regional fibroblast heterogeneity in the lung: implications for remodeling. Am J Respir Crit Care Med. 2006, 173 (11): 1208-1215. 10.1164/rccm.200508-1218OC.View ArticlePubMedPubMed CentralGoogle Scholar
- Burgess JK, Ge Q, Poniris MH, Boustany S, Twigg SM, Black JL, Johnson PR: Connective tissue growth factor and vascular endothelial growth factor from airway smooth muscle interact with the extracellular matrix. Am J Physiol Lung Cell Mol Physiol. 2006, 290 (1): L153-161.View ArticlePubMedGoogle Scholar
- Skold CM: Remodeling in asthma and COPD--differences and similarities. Clin Respir J. 4 (Suppl 1): 20-27.Google Scholar
- Lagente V, Boichot E: Role of matrix metalloproteinases in the inflammatory process of respiratory diseases. J Mol Cell Cardiol. 2010, 48 (3): 440-444. 10.1016/j.yjmcc.2009.09.017.View ArticlePubMedGoogle Scholar
- Veillard F, Lecaille F, Lalmanach G: Lung cysteine cathepsins: intruders or unorthodox contributors to the kallikrein-kinin system?. Int J Biochem Cell Biol. 2008, 40 (6-7): 1079-1094. 10.1016/j.biocel.2007.10.030.View ArticlePubMedGoogle Scholar
- Buhling F, Rocken C, Brasch F, Hartig R, Yasuda Y, Saftig P, Bromme D, Welte T: Pivotal role of cathepsin K in lung fibrosis. Am J Pathol. 2004, 164 (6): 2203-2216. 10.1016/S0002-9440(10)63777-7.View ArticlePubMedPubMed CentralGoogle Scholar
- Deal C: Potential new drug targets for osteoporosis. Nat Clin Pract Rheumatol. 2009, 5 (1): 20-27. 10.1038/ncprheum0977.View ArticlePubMedGoogle Scholar
- Cohen L, E X, Tarsi J, Ramkumar T, Horiuchi TK, Cochran R, DeMartino S, Schechtman KB, Hussain I, Holtzman MJ, et al: Epithelial cell proliferation contributes to airway remodeling in severe asthma. Am J Respir Crit Care Med. 2007, 176 (2): 138-145. 10.1164/rccm.200607-1062OC.View ArticlePubMedPubMed CentralGoogle Scholar
- Turk B, Stoka V: Protease signalling in cell death: caspases versus cysteine cathepsins. FEBS Lett. 2007, 581 (15): 2761-2767. 10.1016/j.febslet.2007.05.038.View ArticlePubMedGoogle Scholar
- Richter A, Puddicombe SM, Lordan JL, Bucchieri F, Wilson SJ, Djukanovic R, Dent G, Holgate ST, Davies DE: The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma. Am J Respir Cell Mol Biol. 2001, 25 (3): 385-391.View ArticlePubMedGoogle Scholar
- Johnson PR, Black JL, Carlin S, Ge Q, Underwood PA: The production of extracellular matrix proteins by human passively sensitized airway smooth-muscle cells in culture: the effect of beclomethasone. Am J Respir Crit Care Med. 2000, 162 (6): 2145-2151.View ArticlePubMedGoogle Scholar
- Ten Hacken NH, Postma DS, Timens W: Airway remodeling and long-term decline in lung function in asthma. Curr Opin Pulm Med. 2003, 9 (1): 9-14. 10.1097/00063198-200301000-00002.View ArticlePubMedGoogle Scholar
- Royce SG, Tan L, Koek AA, Tang ML: Effect of extracellular matrix composition on airway epithelial cell and fibroblast structure: implications for airway remodeling in asthma. Ann Allergy Asthma Immunol. 2009, 102 (3): 238-246. 10.1016/S1081-1206(10)60087-7.View ArticlePubMedGoogle Scholar
- Ebina M, Takahashi T, Chiba T, Motomiya M: Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma. A 3-D morphometric study. Am Rev Respir Dis. 1993, 148 (3): 720-726.View ArticlePubMedGoogle Scholar
- Carroll N, Elliot J, Morton A, James A: The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis. 1993, 147 (2): 405-410.View ArticlePubMedGoogle Scholar
- Johnson PR, Burgess JK, Underwood PA, Au W, Poniris MH, Tamm M, Ge Q, Roth M, Black JL: Extracellular matrix proteins modulate asthmatic airway smooth muscle cell proliferation via an autocrine mechanism. J Allergy Clin Immunol. 2004, 113 (4): 690-696. 10.1016/j.jaci.2003.12.312.View ArticlePubMedGoogle Scholar
- Deng H, Hershenson MB, Lei J, Anyanwu AC, Pinsky DJ, Bentley JK: Pulmonary artery smooth muscle hypertrophy: roles of glycogen synthase kinase-3beta and p70 ribosomal S6 kinase. Am J Physiol Lung Cell Mol Physiol. 2010, 298 (6): L793-803. 10.1152/ajplung.00108.2009.View ArticlePubMedPubMed CentralGoogle Scholar
- Parameswaran K, Willems-Widyastuti A, Alagappan VK, Radford K, Kranenburg AR, Sharma HS: Role of extracellular matrix and its regulators in human airway smooth muscle biology. Cell Biochem Biophys. 2006, 44 (1): 139-146. 10.1385/CBB:44:1:139.View ArticlePubMedGoogle Scholar
- Gabbiani G: The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003, 200 (4): 500-503. 10.1002/path.1427.View ArticlePubMedGoogle Scholar
- Zou Y, Zhang RZ, Sabatelli P, Chu ML, Bonnemann CG: Muscle interstitial fibroblasts are the main source of collagen VI synthesis in skeletal muscle: implications for congenital muscular dystrophy types Ullrich and Bethlem. J Neuropathol Exp Neurol. 2008, 67 (2): 144-154. 10.1097/nen.0b013e3181634ef7.View ArticlePubMedGoogle Scholar
- Faouzi S, Le Bail B, Neaud V, Boussarie L, Saric J, Bioulac-Sage P, Balabaud C, Rosenbaum J: Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an in vivo and in vitro study. J Hepatol. 1999, 30 (2): 275-284. 10.1016/S0168-8278(99)80074-9.View ArticlePubMedGoogle Scholar
- Sullivan DE, Ferris M, Nguyen H, Abboud E, Brody AR: TNF-alpha induces TGF-beta1 expression in lung fibroblasts at the transcriptional level via AP-1 activation. J Cell Mol Med. 2009, 13 (8B): 1866-1876. 10.1111/j.1582-4934.2008.00647.x.View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.